| | MAY 20229IN FOCUSTata Capital Healthcare Fund II (TCHF II), sponsored by Tata Capital, has announced the Final Close of its fund with Investor commitments of Rs.955 crores (US $126 million), meeting its target AUM of Rs.950 crores (excluding green-shoe). This was a follow-up to the Tata Capital Healthcare Fund I which had raised Rs.411 Crore (US $70 mil-lion) in 2012. TCHF II has received commitments from domestic and international financial and strate-gic institutions including some of the global pharma, medical equip-ment companies, development fi-nancial institutions and large Eu-ropean Institutions indicating their support for the TCHF investment strategy. TCHF II is also privileged to receive commitment from the `Self Reliant India (SRI)' Fund of the Government of India under the Ministry of Micro, Small and Medium Enterprises. Visalakshi Chandramouli, Managing Partner of TCHF articulating the Fund's investment strategy said, "TCHF II will seek to achieve returns by principally taking equity positions in healthcare and life sciences re-lated companies having significant business exposure to India. The investment strategy of TCHF II is predicated on the fol-lowing two themes:1. Domestic Healthcare & Life Sciences Consumption: Fo-cused on the Indian consumption story in healthcare and life scienc-es related businesses. It is estimat-ed that 60 percent of TCHF II's in-vestments will cater to this theme.2. Healthcare & Life Sciences Competency: Focused on le-veraging India's expertise in the healthcare and life sciences sec-tors to deliver products/services to the world markets. It is estimated that 40 percent of TCHF IIs invest-ments will cater to this theme.We remain grateful and would like to thank our investors for re-posing faith and trust in the Tata Capital Healthcare Fund fran-chise". Vamesh Chovatia, Partner of TCHF said, "TCHF II is seeking to invest across sub sectors of Phar-maceuticals, Pharma & Allied Ser-vices, Healthcare Delivery, Med-ical Devices & Equipment's and Digital Health. The Fund has al-ready made commitments to three companies in the areas of Domes-tic Pharma Formulations Linux Pharma; Diagnostic Services Atu-laya Healthcare and Digital Health Deeptek and expects to announce its fourth investment shortly. The Fund has a rich pipeline of deals and is expected to continue its deal momentum in the coming months. The Fund will typically look at committing $5mn - $15mn per transaction and potentially a larger ticket size along with co-in-vestment support from its Limit-ed Partners who have committed to invest in the Fund". The $190+ billion Indian healthcare and life sciences market is estimated to grow at a compounded annual growth rate (`CAGR') of 14 percent over the next five years and it rep-resents an attractive investment opportunity. Indian healthcare and life sciences market is the sec-ond fastest growing market in the world. India's population of over 1.3 billion people provides a strong demand driver as there is a signifi-cant mismatch between supply and demand in the healthcare and life sciences sector. The team considers that this supply demand mismatch combined with the world class skill sets of India's healthcare and phar-maceutical professionals make the healthcare and life sciences sector a compelling investment opportu-nity. THE FUND WILL TYPICALLY LOOK AT COMMITTING $5MN - $15MN PER TRANSACTION AND POTENTIALLY A LARGER TICKET SIZE ALONG WITH CO-INVESTMENT SUPPORT FROM ITS LIMITED PARTNERS WHO HAVE COMMITTED TO INVEST IN THE FUNDTATA CAPITAL HEALTHCARE FUND II, HAS ANNOUNCED THE FINAL CLOSE OF ITS FUNDING
< Page 8 | Page 10 >